6Feb2017 A Canadian Biotech Breakaway? /Asher Mullard/0/All, Finance, Strategy, Venture Capital06 Feb 2017 Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.